Please login to the form below

Not currently logged in
Email:
Password:

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

Lilly Strattera atomoxetine ADHD

Adults in the UK with attention deficit hyperactivity disorder (ADHD) who were not prescribed medicine as a child will now have access to Lilly's Strattera after it was approved by the country's regulator.

The Medicines and Healthcare Products Regulatory Agency (MHRA) granted authorisation to expand the indication of Strattera (atomoxetine) to initiate treatment of ADHD in adults, where pre-existing symptoms during childhood can be confirmed by a third-party.

This adds to current indications covering its use to treat children and adolescents, as well as adults whose symptoms persist and who had been prescribed the drug when younger.

The approval will be used as a basis for Lilly to gain EU-wide approval trough the European Medicines Agency (EMA) as part of the region's mutual recognition process.

It is the first time a drug has gained ADHD approval in the EU for a specific adult use, and marks an important step for adults diagnosed with ADHD who were undiagnosed or misdiagnosed for other common mental health disorders during their childhood.

“This can occur because the signs and symptoms of ADHD can overlap with those of other common mental health disorders,” said Professor Philip Asherson, Professor of Clinical and Molecular Psychiatry at King's College London and president of the UK Adult ADHD Network (UKAAN), “and because primary and secondary care mental health services may lack the training and experience required to accurately identify the disorder."

He added: “In some cases this can lead to patients being treated for a personality or mood disorder when the main problem is ADHD.”

According to Prof Asherson, this is especially significant as about two third of children and adolescent with ADHD continue to have symptoms into adulthood.

In the UK alone, 1.7 million adults are estimated to have ADHD, with the condition able to impact family, work and social relationships.

Uptake of Strattera in adults is likely to be influenced by guidance from National Institute for Health and Care Excellence (NICE) and the British Association of Psychopharmacology, both of which state adults with the condition have access to drug treatment.

Strattera's new licence is backed by results from clinical trials that demonstrate it can achieve significant improvements in ADHD symptoms and quality of life outcomes.

4th June 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ogilvy Healthworld

'We have a habit of divine discontent with our performance.It is an antidote to smugness.'So said David Ogilvy. And so...

Latest intelligence

Is telehealth delivering on its promises?
Using new digital technologies to help patients see their doctors online and not need to attend their surgery can help save time and money - but just how well is...
Channel purpose, change lives
GCI Health's Laura Starr on the power of creativity in health and wellness, all founded upon authentic brand purpose....
Wearables: the tangible product of the patient revolution
As the relationship between the patient and his doctor evolve, we look at how new technology is playing its part...

Infographics